

## POSITION DESCRIPTION



## INTERNATIONAL MYELOMA FOUNDATION

### FOR THE POSITION OF PRESIDENT AND CHIEF EXECUTIVE OFFICER

**SUMMER 2025**

---

Much of this material contained herein is gained in confidence and as such should be regarded as confidential. Accordingly, it is understood that dissemination of this material should be limited to those individuals in your organization who are directly connected with this specific search or whom a reasonable person would agree have a need to know.



## POSITION DESCRIPTION

---

POSITION	President and Chief Executive Officer
ORGANIZATION	International Myeloma Foundation
REPORTS TO	Board of Directors
LOCATION	Studio City, CA
WEBSITE	<a href="https://www.myeloma.org/">https://www.myeloma.org/</a>

## TABLE OF CONTENTS

---

ORGANIZATIONAL OVERVIEW	03
ROLE SUMMARY	14
CANDIDATE PROFILE	15
SEARCH TEAM	16



## ORGANIZATIONAL OVERVIEW

---

Founded in 1990, the International Myeloma Foundation (IMF) is a 501(c)(3) not-for-profit charity and the first and largest global foundation focusing specifically on multiple myeloma.

### Our Mission

The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure by focusing on four key areas: research, education, support, and advocacy.

### Our Vision

A world where every myeloma patient can live life to the fullest, unburdened by the disease.

### What We Do

#### Research

##### **Improving Lives, Finding the Cure: The Fight Against Multiple Myeloma Starts Here**

The International Myeloma Foundation is dedicated to finding a cure for those living with multiple myeloma. The quest for a multiple myeloma cure demands constant innovation. Through guidance from the world's foremost experts on multiple myeloma and disease control, the IMF has created with an arsenal of resources with a similar mission — finding a cure for this cancer that develops in nearly 160,000 people annually not to mention the countless numbers of loved ones that myeloma affects. While the fight continues, discover how these research initiatives impact the cause here: <https://www.myeloma.org/our-research>.

##### *Black Swan Research Initiative*

For the world's leading multiple myeloma experts, failure to find the cure for this cancer just isn't an option. We've banded together the world's brightest minds in research, oncology, and health studies to form the IMF's Black Swan Research Initiative® — a leading-edge project that pits our scientists and leaders on the frontlines against myeloma. Together, our mission is to find the first definitive cure for myeloma and help bridge the gap from long-term remission to cure. *Road to the Cure*: The IMF Black Swan Research Initiative is funding several "cure" trials in the U.S. and abroad. They are called "cure" trials because they use a "curative strategy" that aims to treat myeloma early and aggressively. This approach is at the heart of the Black Swan's pathway to a cure.

##### *International Myeloma Working Group*

The International Myeloma Working Group® (IMWG) emerged from the IMF's Scientific Advisory Board which was established in 1995. It became clear that there was a need to conduct collaborative research and produce consensus guidelines for the myeloma community. The first consensus guideline was published in 2003, and the first Annual Brainstorming Summit was organized in Barcelona in 2010. The mission of the IMWG is to conduct collaborative basic, clinical,



**INTERNATIONAL MYELOMA  
WORKING GROUP**



and translational research to improve outcomes for myeloma patients while providing scientifically validated, critically appraised consensus guidelines for the myeloma community globally. The IMWG is one of the most prestigious organizations for myeloma researchers worldwide. Their work has allowed researchers a greater understanding of myeloma and treatments. The IMWG members meet each year in December to be informed and included in current and new research projects.

#### *Asian Myeloma Network*

Established by the IMF at a meeting in Singapore in 2011, the Asian Myeloma Network® (AMN) is the first of its kind in the region and is comprised of myeloma experts from China, Hong Kong, Malaysia, Taiwan, Japan, Philippines, Singapore, South Korea, Vietnam, and Thailand. The AMN has taken the lead in projects to assist IMF in providing physician education and patient support throughout Asia. Since its founding, the AMN has: created a unified database to assess the incidence of myeloma in Asian countries as a basis for establishing region-specific treatment management tools and strategies; launched and overseen clinical trials; enabled myeloma patients to gain access to the newest myeloma treatments; developed informational resource materials in local languages, especially for patients and caregivers; and engaged in collaborative studies.

#### *Latin American Myeloma Network*

The IMF has created the Latin American Myeloma Network (LAMN) to conduct multinational trials, provide myeloma education to patients and providers, facilitate collaborative research, and deepen the myeloma expertise across the region of Latin America. It also serves to bring Latin American expertise to the wider global program of the IMF, including the IMF International Myeloma Working Group.



**LATIN AMERICA  
MYELOMA NETWORK**

Current member countries of the LAMN include top myeloma investigators from Argentina, Brazil, Chile, Colombia, and Uruguay. The first clinical trial LAMN001 is soon to be launched for early relapsed disease.

#### *Brian D. Novis Research Grants*

In 1995, the IMF established the Brian D. Novis Research Grant program in memory of its co-founder. The grants are awarded annually to promote research in all areas of myeloma to improve patient outcomes. To date, the IMF has funded more than 100 of the most promising projects by both senior and junior investigators in the field of multiple myeloma.

#### *Nurse Leadership Board*

In 2006, the IMF founded the Nurse Leadership Board® as a professional partnership to represent oncology nurses who are experts in the care of multiple myeloma patients at leading medical centers. The NLB is improving the nursing care and self-care of patients with multiple myeloma via publications, symposia, multimedia, and research. *Myeloma University - A Comprehensive Online Educational Program on Multiple Myeloma*, was created by IMF's Nurse Leadership Board as an online educational program specially designed for nurses and other healthcare professionals to gain knowledge about multiple myeloma. *New Therapies and Regimens for Patients with Multiple Myeloma: Case Studies for Nurses* is an educational activity aiming to equip healthcare professionals, particularly nurses, with up-to-date knowledge and practical strategies for managing patients with multiple myeloma.



**NURSE LEADERSHIP  
BOARD**



## Education

Because "Knowledge Is Power," the IMF brings educational seminars and workshops to communities near you and provides a library of publications on multiple myeloma care. Information IMP provides includes:

### *Downloadable Cancer Publications*

For the most current information about multiple myeloma, online access is given to IMF's library of more than 100 cancer articles, journals, and other publications for patients, caregivers, and healthcare professionals. All are available free of charge online and in printed copy by mail. Many core booklets and key medical articles are translated in 20+ languages as well.

### *IMF Videos*

The IMF is committed to improving lives and finding the cure. From our weekly educational videos with leading myeloma experts to comprehensive news from key medical cancer conferences around the world, IMF videos are your all-access ticket to critical myeloma research, patient education, and guidance. Content is updated regularly. The lifetime views of IMF videos is 3.8 million, with 872,000+ views in the last year alone. The IMF's website, [myeloma.org](http://myeloma.org), connects to the IMF's YouTube channel, which houses thousands of these videos.

### *Patient and Family Seminars*

For educational patient and caregiver support in your hometown, the IMF hosts Patient & Family Seminars in the U.S. and Europe.

## Support

Since our inception in 1990, the IMF has supported and met in-person with thousands of patients globally. At our annual Support Group Leaders Summit, the reach is to more than 6,000 patients and care partners (or, caregivers).

### *Support Group*

IMF has facilitated a network of 160 myeloma-specific support groups that hold regular meetings in the U.S. No matter where you are, we can help you find or create a multiple myeloma support group and connect with other survivors and caregivers.

### *Resources and Support*

Multiple myeloma is a disease that can often be treated successfully, and many patients live long and productive lives after being diagnosed. We are here to arm you with as much patient information as possible so that you can seek out the very best care, while working toward better treatments and a cure.

### *Publications and Videos*

The IMF produces multiple myeloma publications for patients and caregivers, and healthcare professionals. Read, download, or order printed copies.



### *InfoLine*

The IMF's InfoLine is here for you for your myeloma-related questions and concerns. The InfoLine team consistently provides the best information about myeloma in a caring and compassionate manner. The InfoLine does this through responding to live calls as well as email inquiries. Also, the InfoLine has a scheduling system, which allows patients and their loved ones to access an IMF Information Specialist at a time that works for them.

### **Advocacy**

The IMF's Advocacy team has educated and empowered thousands of individuals who make a positive impact each year on issues critical to the myeloma community in the U.S. and worldwide.

*IMF Advocacy Initiatives* The IMF's Advocacy Program helps guide individuals to advocate for critical health issues that affect the multiple myeloma community. The IMF will work with you at the state and local level to support legislation to improve the lives of U.S.-based myeloma patients. Recently, the IMF successfully advocated for the Cancer Drug Parity Act, a bipartisan legislation that ensures patients do not pay more out of pocket for oral anticancer medications than they would for IV chemotherapy.

### *Veterans Against Myeloma*

The IMF's Veterans Against Myeloma website provides key links to relevant VA websites, to state veterans assistance offices and to national veterans service organizations whose service officers help vets.

### *Global Myeloma Action Network (GMAN)*

The IMF's Global Myeloma Action Network® (GMAN®) is a global coalition of myeloma patient organizations representing over 40 countries.

GMAN works in collaboration with patients, caregivers, physicians/KOLs, policymakers, the pharmaceutical industry and other global stakeholders.

While each member organization executes its own vision and mission, GMAN works to increase global awareness of multiple myeloma, improve access to timely diagnosis and critical medicines as well as provide capacity-building support to our national member organizations.

### **Our 2023-2027 Global Strategy Plan**

The International Myeloma Foundation has a rich history spanning over three decades and an unparalleled global myeloma community united under the mission of improving the quality of life for myeloma patients and working towards prevention and a cure. Read more about the Strategic Plan here: <https://www.myeloma.org/2023-2027-global-strategy-plan>.

The Strategic Plan Revolves Around Three Key Objectives:

1. **RAISE THE BAR:** Examine the why of all our actions to ensure they are purpose-driven, meaningful, and effective.



2. **BROADEN OUR REACH:** Address unmet patient needs by expanding our reach to diverse and underserved populations in everything we do.
3. **INNOVATE EVERY STEP OF THE WAY:** Provide those who need it most with what they need the most, throughout their myeloma journeys.

## Our Three Key Organizational Strategies

As outlined, International Myeloma Foundation (IMF)'s work is driven by the foundational pillars of Research, Education, Support, and Advocacy, and implemented through **three key organizational strategies**:

### 1. Providing Comprehensive Global Patient Experience

The IMF is committed to meeting patients where they are—geographically, technologically, and emotionally. We leverage digital tools to ensure timely, personalized access to information and support across the globe. Our innovations include Myelo®, a 24/7 AI-powered chatbot that answers patient questions; our Clinical Trials Matching Engine, which tailors clinical trial options to each patient's diagnosis and preferences; and our Myeloma Knowledge Platform, which integrates and analyzes previously siloed data to provide personalized guidance. These tools, along with a robust offering of webinars, videos, podcasts, publications, personalized phone support, and live events, form the IMF's Global Comprehensive Patient Experience 2.0—a coordinated network of resources that empower patients to make informed decisions and improve their overall journey with myeloma.

### 2. Collecting and Harnessing Real-World Data

We lead multiple large-scale initiatives to gather and apply real-world data that fuels discovery and improves outcomes:

- [iStopMM](#), the world's largest multiple myeloma screening study, based in Iceland.
- The [Immune Therapy Registry](#), the first global, prospective registry for patients with relapsed or high-risk disease receiving immune-based therapies.
- A [Virtual Tissue Bank](#), which supports global collaboration by collecting, storing, and sharing blood and bone marrow data for analysis of genetic and immune markers.
- Cure-focused clinical trials such as ASCENT and CESAR, which aim to prevent disease progression and achieve lasting remission.

These initiatives generate invaluable data and create a scalable model for collaborative, patient-centered research.

### 4. Addressing the World's Most Critical Research Questions

The IMF focuses on identifying and answering the most urgent and transformative research questions in myeloma. Guided by our Scientific Advisory Board, a panel of world-renowned myeloma experts, we prioritize projects with the potential to significantly accelerate progress toward a cure.



Additionally, our International Myeloma Working Group, comprised of more than 300 global myeloma researchers, sets the bar for guidelines for myeloma diagnosis and treatment worldwide.

By securing funding and fostering global collaboration, we ensure that research is driven by scientific need and patient benefit—not by market forces alone. Together, these strategies enable the IMF to lead with purpose, innovate with integrity, and center on patients in every step toward a future without multiple myeloma.

## Financial Reports

The International Myeloma Foundation, 501(c)(3) not-for-profit charity, began operations in 1990. Research to find a cure is paramount to our mission, while patient support, education, and advocacy are our core values. Thanks to our generous donors, advocates, and volunteers, approximately 90% of every dollar we spend goes directly to research and patient-focused programs, earning us top marks from the nation's most trusted charity evaluators year after year.

### Top Rankings

Because of these efforts, the IMF is proud to share that we consistently earn top rankings from the nation's leading charity evaluators. This past year, we received the highest four-star rating for the 17th time from Charity Navigator.

View IMF's Annual Reports and Audit Reports here:

<https://www.myeloma.org/financials>.







Financials as of 9/2024 - [IMF-Annual-Report-2024 by International Myeloma Foundation - Issuu](#)

INTERNATIONAL MYELOMA FOUNDATION

(A California Nonprofit Public Benefit Corporation)

**Statement of Financial Position  
September 30, 2024**

**ASSETS**

**CURRENT ASSETS**

Cash and cash equivalents	\$ 3,121,950
Investments, at fair value	9,881,953
Contributions, program grants, and other receivables	1,292,900
Prepaid expenses	<u>737,852</u>

**Total Current Assets** 15,034,655

**OTHER ASSETS**

Property and equipment, net	958,745
Intangible assets, net	58,039
Right-of-use asset, operating lease	809,157
Security deposits	<u>21,407</u>

**Total Other Assets** 1,847,348

**TOTAL ASSETS** \$ 16,882,003

**LIABILITIES AND NET ASSETS**

**LIABILITIES**

Accounts payable and accrued expenses	\$ 2,537,767
Right-of-use liability, operating lease, current portion	164,862
Deferred program and educational grant revenues	<u>3,207,010</u>

**Total Current Liabilities** 5,909,639

**OTHER LIABILITIES**

Right-of-use liability, operating lease	672,227
Gift annuity obligation	<u>48,037</u>

**TOTAL LIABILITIES** 6,629,903

**NET ASSETS**

Without donor restrictions	9,929,684
With donor restrictions	<u>322,416</u>

**TOTAL NET ASSETS** 10,252,100


**TOTAL LIABILITIES AND NET ASSETS** \$ 16,882,003



INTERNATIONAL MYELOMA FOUNDATION  
(A California Nonprofit Public Benefit Corporation)

**Statement of Activities and Changes in Net Assets  
for the Year Ended September 30, 2024**

	Without Donor Restrictions	With Donor Restrictions	Total
<b>REVENUES AND SUPPORT</b>			
Educational and program grants	\$ 7,746,127	\$ 1,310,072	\$ 9,056,199
General contributions	2,044,963	863,948	2,908,911
Contributed non-financial assets	581,392	-	581,392
Clinical trials and research revenue	5,740,847	-	5,740,847
Change in split interest agreements	-	(5,229)	(5,229)
Support group income	18,667	-	18,667
Fundraising events, net of direct benefit to donors of \$408,807	-	300,336	300,336
Investment income, net of advisory fees of \$69,920	1,905,634	23,575	1,929,209
	18,037,630	2,492,702	20,530,332
Transfer to annuity assets	(7,811)	7,811	-
Net assets released from restrictions	2,387,784	(2,387,784)	-
<b>TOTAL REVENUES AND SUPPORT</b>	<b>\$ 20,417,603</b>	<b>\$ 112,729</b>	<b>\$ 20,530,332</b>
<b>FUNCTIONAL EXPENSES</b>			
Program expenses	18,419,062	-	18,419,062
General supporting expenses	991,287	-	991,287
Fundraising	1,385,727	-	1,385,727
<b>TOTAL FUNCTIONAL EXPENSES</b>	<b>\$ 20,796,076</b>	<b>-</b>	<b>\$ 20,796,076</b>
<b>CHANGE IN NET ASSETS</b>	<b>(378,473)</b>	<b>112,729</b>	<b>(265,744)</b>
<b>NET ASSETS</b> - Beginning of year	<b>10,308,157</b>	<b>209,687</b>	<b>10,517,844</b>
<b>NET ASSETS</b> - End of year	<b>\$ 9,929,684</b>	<b>\$ 322,416</b>	<b>\$ 10,252,100</b>





INTERNATIONAL MYELOMA FOUNDATION  
 (A California Nonprofit Public Benefit Corporation)  
**Statement of Functional Expenses  
 for the Year Ended September 30, 2024**

**Breakdown of Expenses by Program**

PROGRAM	TOTAL EXPENSES
Research	\$ 8,037,016
Education and Awareness	2,745,422
Patient and Family Seminars	1,819,719
International	1,237,997
Support Groups	1,813,419
Nurse	737,293
Website	497,221
Advocacy	433,644
InfoLine	382,761
Myeloma Today	333,326
Clinical Meetings	314,822
Information Mailings	66,422
<b>Total Program Expenses</b>	<b>\$ 18,419,062</b>
General Supporting Expenses	991,267
Fundraising Expenses	1,385,727
<b>Total Expenses</b>	<b>\$ 20,796,076</b>

**Our People**



The people of the IMF — our Board of Directors, our management, and our staff — are here to help you. We invite you to learn more about our team. <https://www.myeloma.org/board-of-directors-staff>





## Our Scientific Advisory Board



The IMF has assembled a global dream team of renowned myeloma experts. We leverage the Scientific Advisory Board's collective knowledge and experience to identify new areas of research, collaborate on international research initiatives, and strengthen the scientific rigor of ongoing projects.

The Scientific Advisory Board is an esteemed group of global myeloma experts (led by IMF Chairperson of the Board Dr. S. Vincent Rajkumar), who guide and prioritize IMF research initiatives as well as identify areas for investment and expansion.

<https://www.myeloma.org/international-myeloma-foundation-scientific-advisory-board>

## Our Partners

We partner with organizations all over the world. Together, we promote awareness of multiple myeloma, encourage measures to prevent and combat the disease, and advocate for health issues that affect the multiple myeloma community.

<https://www.myeloma.org/about-us/affiliates>



## Our International Partners and Affiliates

### *Korea Blood Disease & Cancer Association*

The Korea Blood Disease & Cancer Association (KBDCA) is a “non-profit organization that helps patients to cope with the disease through economic and emotional support and work on a variety of disease education programs to help people understand the disease and make their life better.” They make



periodical publications and distribute them free of charge. The IMF is committed to working with our Korean partners to enhance access to anti-myeloma therapies and are pleased the KBCA is involved with clinical trials conducted by the IMF's Asian Myeloma Network.

#### *Myeloma Australia*

Myeloma Australia provides information and caring support to those living with myeloma via specialist myeloma nurses, educates those involved in patient care and treatment, raises community awareness and understanding of multiple myeloma, and works to improve patient access to the latest treatments at affordable prices.

#### *Myeloma Canada*

Myeloma Canada is an organization created by, and for, people living with multiple myeloma. Its mission is to improve the lives of Canadians impacted by multiple myeloma by accelerating access to better care through awareness, education, advocacy, community engagement, and clinical research. Its Myeloma Canada Research Network is comprised of 24 centers in 9 provinces across Canada.

#### *Myeloma China*

On September 9, 2010, the International Myeloma Foundation signed a cooperative agreement with the Chinese Health Promotion Foundation (CHPF), an agency that operates under the Chinese Ministry of Health, to promote awareness of multiple myeloma in China and to encourage measures to prevent and combat the disease. This agreement substantially expands IMF's presence in Asia and will support the thousands of multiple myeloma patients in China. IMF works in close cooperation with the Chinese Myeloma Committee, especially in physician education.

#### *Czech Myeloma Group*

The Czech Myeloma Group (CMG) was established in 1996. The main objective of CMG is to organize and coordinate research and clinical activities in the Czech Republic in multiple myeloma. It ensures that the best current standards of care for patients with multiple myeloma are met. Its clinical studies provide Czech patients with multiple myeloma the access to the latest experimental treatments in the field.

#### *Myeloma Patients Europe*

Myeloma Patients Europe (MPE) is an umbrella organization of multiple myeloma patient groups and associations from across Europe. MPE was formed following the merger in 2011 of the European Myeloma Platform and Myeloma Euronet.

#### *AMEN Association*

AMEN, the Israeli association of multiple myeloma patients, was established in 2005 by myeloma patients for the sake of other Israeli patients and their family members. AMEN distributes information about multiple myeloma, collaborates with medical centers, and accompanies new patients in their first steps of a journey with myeloma.

#### *IMF in Japan*

The IMF has enjoyed a long history of patient support in Japan. Efforts are underway to establish a cooperative structure to be able to provide up-to-date information to Japanese patients. As a first step, the IMF is working in cooperation with the medical association, the Japan Myeloma Society, to develop a website in the Japanese language for multiple myeloma patients in Japan.

#### *IMF Latin America*



The IMF Latin America was founded in 2004 in Brazil by Christine Jerez Telles Battistini, the daughter of a patient with multiple myeloma, and Dr. Vania Tietsche de Moraes Hungria, a hematologist who specializes in multiple myeloma. Dr. Hungria is the Director of the Medical Clinic San Germano and a member of the IMF's International Myeloma Working Group (IMWG). IMF Latin America aims to bring to patients and the medical community of South America the same services available today in the United States, the United Kingdom, and Japan.

#### *IMF in Turkey*

The IMF partners with the Cancer Support group Kanser Savaşçıları, formally known as Miyelomla Yaşam, which is dedicated to improving the lives of all types of cancer patients in Turkey. Based in Istanbul, it is the official umbrella organization for cancer associations and aims to empower through awareness, education, and support.

## ROLE SUMMARY

---

The International Myeloma Foundation (IMF) is the highly respected, leading voice for the multiple myeloma cancer community. As the premier US-based, global-servicing organization devoted to advancing myeloma cancer research and supporting those touched by the disease, IMF impacts the lives of hundreds of thousands of people across the globe.

Through our website, [www.myeloma.org](http://www.myeloma.org) and educational offerings, IMF provides patients and caregivers with the resources and support services needed to navigate the myeloma journey. Through our Brian D. Novis Research Grants Awards, and our annual Gala, International Myeloma Working Group and Black Swan Research Initiative, IMF promotes, and funds collaborative and cutting-edge research programs focused on improving the diagnosis and treatment of myeloma, with the ultimate goal of finding a cure. The IMF's annual budget has increased dramatically over the past five years, and, despite the Covid-19 pandemic, the IMF is in sound financial condition. An eighteen-member Board of Directors governs IMF. Our Board is committed to the long-term growth of the IMF and places great emphasis on ensuring that development opportunities at all levels are initiated and implemented to enable the IMF to continue to grow and make an impact on the myeloma community. The Board has recently approved the strategic plan, which includes continuing the growth of our research programs; increasing our educational offerings; expanding the reach of our patient support programs and fostering an active grassroots advocacy initiative.

The position requires an experienced and charismatic leader to serve as the CEO, preferably an individual with a deep passion for and connection to myeloma care, either as a patient, care partner, researcher or physician. The CEO will guide all aspects of the implementation of IMF's program development for the myeloma cancer community, manage day-to-day operations, provide direction and actively participate in fund-raising, and provide strategic direction and guidance to the leadership team, department heads and Board of Directors. The CEO will ensure that the organization's approximately \$20M annual budget is used and deployed to the benefit of the myeloma community and that all resources are used in support of the organization's mission. The CEO must communicate effectively, foster and maintain a positive and collaborative work environment, and build successful relationships with and among multiple constituencies, including the Board, staff, volunteers, donors, medical professionals, and pharmaceutical partners.



## Responsibilities

- ▼ Working with senior management, create and implement IMF's annual and strategic development plans to identify and secure the necessary resources, financial and otherwise, to accomplish IMF's mission and to enable IMF to continue to grow.
- ▼ Strengthen relationships with current funding entities, including private and corporate foundations.
- ▼ Expand and broaden future foundation funding prospects.
- ▼ Oversee strategic and tactical implementation of all programs, outreach, and growth.
- ▼ Manage multiple complex projects simultaneously, providing timely input and follow-up through to completion.
- ▼ In close collaboration with the CFO, prepare and implement the annual budget and assist the CFO in the preparation of the annual audit, monthly financials, and tax returns.
- ▼ Ensure that the IMF has the appropriate structure and properly trained staff to carry out its mission.
- ▼ Ensure that appropriate programs, policies, systems, and procedures are in place; that the IMF complies with relevant legal mandates; and work closely with IMF's legal counsel.
- ▼ Maintain positive relationships with Board Members, associations, donors, volunteers and government representatives, and with the financial, business, and medical communities, such that all constituencies are working to foster the growth and development of IMF.
- ▼ Represent IMF professionally as necessary at public functions, including making effective public presentations, media appearances etc.
- ▼ Provide ongoing strategic direction, working with the Board to guide IMF toward its short and long-term goals.

## CANDIDATE PROFILE

---

### Qualifications

- ▼ Bachelor's Degree required, a Master's degree is preferred.
- ▼ Minimum of 7 to 10 years leadership experience.
- ▼ Exceptional leadership skills gained through roles in not-for-profit, corporate or medical roles and a track record of success in achieving organizational goals.
- ▼ A deep passion for and connection to myeloma care, either as a patient, care partner, researcher or physician.
- ▼ Inspirational and visionary leader with a track record of achieving success through others.
- ▼ Strategic planning skills, including collaboration with the Board in concert with leading the executive team in developing a strategic plan and providing regular updates on the strategic plan based upon changing market conditions and national trends.



- ▼ Be a champion of innovation. Advocate for new ideas, technologies, and processes by challenging the status quo, aligning business goals and technology to move initiatives forward.
- ▼ Significant experience with philanthropy, as a Board member, donor or a fundraiser, with experience in major gifts, corporate and foundation funding and annual giving campaigns.
- ▼ Demonstrate financial acumen with understanding of budgets, grants, restricted funds, etc.
- ▼ Exceptional written and verbal communication skills with strong executive presence and exceptional public speaking skills. Media training a plus.
- ▼ Strong interpersonal skills and experience working with multiple diverse constituencies to build and execute a shared vision.
- ▼ Self-directed, grounded and collaborative leader who can facilitate change.
- ▼ Creative problem solver, flexible and capable of adapting to changing priorities.
- ▼ Strategic thinker, capable of moving IMF to new levels.
- ▼ Experience working with independent Boards of Directors.
- ▼ Supervisory experience across a broad range organizational disciplines (fund-raising, marketing, publications, medical education, etc.) as well as experience managing remote teams in multiple countries.

## SEARCH TEAM

---

### **Lyn Brennan**

#### **Managing Director**

212-542-2585

[Lyn.Brennan@divsearch.com](mailto:Lyn.Brennan@divsearch.com)

### **Betsy Mullenix**

#### **Senior Associate**

314-449-1584

[mullenix@grantcooper.com](mailto:mullenix@grantcooper.com)

### **Setta Gilkey**

#### **Executive Assistant**

530-565-6050

[Setta.Gilkey@divsearch.com](mailto:Setta.Gilkey@divsearch.com)